EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mesonephric‐Like Adenocarcinoma of the Endometrium and the Impact of the Updated 2023 FIGO Staging System

Joy Ogunmuyiwa iD, Alexandra Hamilton iD, Judy Hayek iD, Jocelyn Ogunmuyiwa iD, Constantine Gorelick iD, Daniel Levitan iD, Hani Ashamalla iD

Case Reports in Obstetrics and Gynecology · 2026-01 · 2026 (1)

DOI: 10.1155/crog/9935815 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Case Reports in Obstetrics and Gynecology, online erschienen am 09.05.2026. Verfasst von Joy Ogunmuyiwa und 6 weiteren Autor:innen. Beteiligte Einrichtung: NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, USA, nyp.org. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mesonephric adenocarcinomas are rare neoplasms derived from remnants of the paired mesonephric ducts. Neoplasms arising from the uterine corpus that are morphologically and immunohistochemically similar to true mesonephric carcinomas, but do not arise from mesonephric remnants, are termed “mesonephric‐like” adenocarcinomas. The diagnosis of mesonephric‐like adenocarcinoma is pathologically challenging. These tumors often exhibit a mixture of morphologic patterns of more common adenocarcinomas. Although their morphologic, immunohistochemical, and molecular profiles have been recently defined, much remains unknown about mesonephric‐like adenocarcinomas. A better understanding of mesonephric‐like andenocarcinoma’s pathogenesis and molecular classification is needed to improve diagnosis and guide management of this rare and aggressive subtype of endometrial cancer. An updated International Federation of Gynecology and Obstetrics (FIGO) staging system for endometrial carcinoma was introduced in June 2023, upstaging aggressive histological subtypes such as mesonephric‐like adenocarcinoma. In this report, we describe a patient with mesonephric‐like adenocarcinoma arising in the uterine corpus, highlight the clinical significance of 2023 FIGO restaging, and discuss the multidisciplinary approach to treatment.

Autor:innen und Institutionen

  • NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, USA, nyp.org.
  • NewYork-Presbyterian Weill Cornell Medical Center, New York, USA, nyp.org.
  • University of Medicine and Health Sciences, Basseterre, Saint Kitts and Nevis, umhs-sk.org.

ORCID-Profile: Joy Ogunmuyiwa, Alexandra Hamilton, Judy Hayek, Jocelyn Ogunmuyiwa, Constantine Gorelick, Daniel Levitan, Hani Ashamalla

Zitieren

APA

Ogunmuyiwa, J., Hamilton, A., Hayek, J., Ogunmuyiwa, J., Gorelick, C., Levitan, D., & Ashamalla, H. (2026). Mesonephric‐Like Adenocarcinoma of the Endometrium and the Impact of the Updated 2023 FIGO Staging System. Case Reports in Obstetrics and Gynecology, 2026(1). https://doi.org/10.1155/crog/9935815

Vancouver

Ogunmuyiwa J, Hamilton A, Hayek J, Ogunmuyiwa J, Gorelick C, Levitan D, et al. Mesonephric‐Like Adenocarcinoma of the Endometrium and the Impact of the Updated 2023 FIGO Staging System. Case Reports in Obstetrics and Gynecology. 2026;2026(1). doi:10.1155/crog/9935815

BibTeX
@article{Ogunmuyiwa2026,
  author = {Ogunmuyiwa, Joy and Hamilton, Alexandra and Hayek, Judy and Ogunmuyiwa, Jocelyn and Gorelick, Constantine and Levitan, Daniel and Ashamalla, Hani},
  title = {Mesonephric‐Like Adenocarcinoma of the Endometrium and the Impact of the Updated 2023 FIGO Staging System},
  journal = {Case Reports in Obstetrics and Gynecology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crog/9935815}
}
Kostenlos starten →